Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways

Han,Yong‑Seok; Lee,Jun  Hee; Lee,Sang  Hun

doi:10.3892/mmr.2015.3804

Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways

Authors:
- Yong‑Seok Han
- Jun Hee Lee
- Sang Hun Lee
View Affiliations

Affiliations: Laboratory for Medical Science Research Institute, Soonchunhyang University, Seoul Hospital, Seoul 336‑745, Republic of Korea, Department of Physiology, Laboratory for Vascular Medicine and Stem Cell Biology, Medical Research Institute, School of Medicine, Pusan National University, Yangsan, Gyeongsangnam-do 626‑870, Republic of Korea
Published online on: May 21, 2015 https://doi.org/10.3892/mmr.2015.3804
Pages: 3446-3452
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fucoidan, a sulfated polysaccharide, has a variety of biological activities, including anti-cancer, anti-angiogenic and anti-inflammatory effects. However, the underlying mechanisms of fucoidan as an anti‑cancer agent remain to be elucidated. The present study examined the anti‑cancer effect of fucoidan on HT‑29 human colon cancer cells. The cell growth of HT29 cells was significantly decreased following treatment with fucoidan (200 µg/ml). In addition, fucoidan inhibited the migration of HT‑29 cells by decreasing the expression levels of matrix metalloproteinase‑2 in a dose‑dependent manner (0‑200 µg/ml). The underlying mechanism of these inhibitory effects included the downregulation of phosphoinositide 3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) by treatment with fucoidan. Furthermore, fucoidan increased the expression of cleaved caspase‑3 and decreased cancer sphere formation. The present study suggested that fucoidan exerts an anti‑cancer effect on HT‑29 human colon cancer cells by downregulating the PI3K‑Akt‑mTOR signaling pathway. Therefore, fucoidan may be a potential therapeutic reagent against the growth of human colon cancer cells.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Chung KY and Saltz LB: Adjuvant therapy of colon cancer: current status and future directions. Cancer J. 13:192–197. 2007. View Article : Google Scholar : PubMed/NCBI
3	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar :
4	Macdonald JS and Astrow AB: Adjuvant therapy of colon cancer. Semin Oncol. 28:30–40. 2001. View Article : Google Scholar : PubMed/NCBI
5	Mann JR, Backlund MG and DuBois RN: Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol. 2:202–210. 2005. View Article : Google Scholar : PubMed/NCBI
6	Li B, Lu F, Wei X and Zhao R: Fucoidan: structure and bioactivity. Molecules. 13:1671–1695. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yamasaki-Miyamoto Y, Yamasaki M, Tachibana H and Yamada K: Fucoidan induces apoptosis through activation of caspase-8 on human breast cancer mcf-7 cells. J Agric Food Chem. 57:8677–8682. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bilan MI, Grachev AA, Ustuzhanina NE, Shashkov AS, Nifantiev NE and Usov AI: Structure of a fucoidan from the brown seaweed Fucus evanescens C.Ag. Carbohydr Res. 337:719–730. 2002. View Article : Google Scholar : PubMed/NCBI
9	Gideon TP and Rengasamy R: Toxicological evaluation of fucoidan from Cladosiphon okamuranus. J Med Food. 11:638–642. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lee JB, Hayashi K, Hashimoto M, Nakano T and Hayashi T: Novel antiviral fucoidan from sporophyll of Undaria pinnatifida (Mekabu). Chem Pharm Bull (Tokyo). 52:1091–1094. 2004. View Article : Google Scholar
11	Aisa Y, Miyakawa Y, Nakazato T, et al: Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways. Am J Hematol. 78:7–14. 2005. View Article : Google Scholar
12	Koyanagi S, Tanigawa N, Nakagawa H, Soeda S and Shimeno H: Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol. 65:173–179. 2003. View Article : Google Scholar
13	Dürig J, Bruhn T, Zurborn KH, Gutensohn K, Bruhn HD and Béress L: Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro. Thromb Res. 85:479–491. 1997. View Article : Google Scholar : PubMed/NCBI
14	McClure MO, Moore JP, Blanc DF, et al: Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Res Hum Retroviruses. 8:19–26. 1992. View Article : Google Scholar : PubMed/NCBI
15	Itoh H, Noda H, Amano H, Zhuaug C, Mizuno T and Ito H: Antitumor activity and immunological properties of marine algal polysaccharides, especially fucoidan, prepared from sargassum thunbergii of phaeophyceae. Anticancer Res. 13:2045–2052. 1993.PubMed/NCBI
16	Zhuang C, Itoh H, Mizuno T and Ito H: Antitumor active fucoidan from the brown seaweed, umitoranoo (Sargassum thunbergii). Biosci Biotechnol Biochem. 59:563–567. 1995. View Article : Google Scholar : PubMed/NCBI
17	Alekseyenko TV, Zhanayeva SY, Venediktova AA, et al: Antitumor and antimetastatic activity of fucoidan, a sulfated polysaccharide isolated from the Okhotsk Sea Fucus evanescens brown alga. Bull Exp Biol Med. 143:730–732. 2007.In English, Russian. View Article : Google Scholar
18	Coombe DR, Parish CR, Ramshaw IA and Snowden JM: Analysis of the inhibition of tumour metastasis by sulphated polysaccharides. Int J Cancer. 39:82–88. 1987. View Article : Google Scholar : PubMed/NCBI
19	Riou D, Colliec-Jouault S, Pinczon du Sel D, et al: Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Anticancer Res. 16:1213–1218. 1996.PubMed/NCBI
20	Ye J, Li Y, Teruya K, et al: Enzyme-digested fucoidan extracts derived from seaweed mozuku of cladosiphon novae-caledoniae kylin inhibit invasion and angiogenesis of tumor cells. Cytotechnology. 47:117–126. 2005. View Article : Google Scholar
21	Bilan MI, Grachev AA, Ustuzhanina NE, Shashkov AS, Nifantiev NE and Usov AI: A highly regular fraction of a fucoidan from the brown seaweed Fucus distichus L. Carbohydr Res. 339:511–517. 2004. View Article : Google Scholar : PubMed/NCBI
22	WCRF/AICR: Policy and Action for cancer prevention. Food, nutrition and physical activity: A global perspective. World cancer research fund and American Institute for Cancer Research; 2009
23	Rajamanickam S and Agarwal R: Natural products and colon cancer: current status and future prospects. Drug Dev Res. 69:460–471. 2008. View Article : Google Scholar
24	Hill MM and Hemmings BA: Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther. 93:243–251. 2002. View Article : Google Scholar : PubMed/NCBI
25	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
26	Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
27	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
28	Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
29	Ye M, Hu D, Tu L, et al: Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci. 49:497–504. 2008. View Article : Google Scholar : PubMed/NCBI
30	Faivre S, Kroemer G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 5:671–688. 2006. View Article : Google Scholar : PubMed/NCBI
31	Burleson KM, Boente MP, Pambuccian SE and Skubitz AP: Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 4:62006. View Article : Google Scholar : PubMed/NCBI
32	L'Espérance S, Bachvarova M, Tetu B, Mes-Masson AM and Bachvarov D: Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics. 9:992008. View Article : Google Scholar : PubMed/NCBI
33	Shield K, Riley C, Quinn MA, Rice GE, Ackland ML and Ahmed N: Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 6:112007. View Article : Google Scholar : PubMed/NCBI
34	Zietarska M, Maugard CM, Filali-Mouhim A, et al: Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog. 46:872–885. 2007. View Article : Google Scholar : PubMed/NCBI